Therapy Areas: Central Nervous System
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
6 March 2025 - Clinical-stage pharmaceutical company Plus Therapeutics Inc (Nasdaq:PSTV) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) ...
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
4 March 2025 - Clinical-stage biotechnology company Latigo Biotherapeutics announced on Monday that it has received Fast Track designation (FTD) from the US Food and Drug Administration (FDA) for LTG-...
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
12 February 2025 - Biopharmaceutical company GenSight Biologics (Euronext: SIGHT) on Wednesday announced final efficacy and safety results from the REFLECT Phase III trial for LUMEVOQ (GS010; lenadoge...
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
7 February 2025 - Alternative investment firm Bain Capital announced on Friday that it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) in a carve-out transacti...
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
17 January 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) and pharmaceutical company Jiangsu Aosaikang Pharmaceutical Co Ltd (ASK Pharm) (SZ:002755) announced on Thursday...
Anavex reports positive long-term data for blarcamesine in early Alzheimer's disease
13 January 2025 - Clinical-stage biopharmaceutical company Anavex Life Sciences Corp (Nasdaq: AVXL) on Monday reported data showing that over three years of continuous treatment with blarcamesine demo...